0001242616-12-000014.txt : 20120531
0001242616-12-000014.hdr.sgml : 20120531
20120531160736
ACCESSION NUMBER: 0001242616-12-000014
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20120529
FILED AS OF DATE: 20120531
DATE AS OF CHANGE: 20120531
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ALLEN LEE F MD PhD
CENTRAL INDEX KEY: 0001408474
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-10865
FILM NUMBER: 12880612
MAIL ADDRESS:
STREET 1: C/O AMAG PHARMACEUTICALS, INC.
STREET 2: 125 CAMBRIDGEPARK DRIVE, 6TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS INC.
CENTRAL INDEX KEY: 0000792977
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 042742593
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 6174983300
MAIL ADDRESS:
STREET 1: 100 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: ADVANCED MAGNETICS INC
DATE OF NAME CHANGE: 19920703
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0305
4
2012-05-29
0
0000792977
AMAG PHARMACEUTICALS INC.
AMAG
0001408474
ALLEN LEE F MD PhD
C/O AMAG PHARMACEUTICALS, INC.
100 HAYDEN AVENUE
LEXINGTON
MA
02421
0
1
0
0
EVP, Chief Medical Officer
Common Stock
2012-05-29
4
C
0
1354
A
3583
D
Common Stock
2012-05-29
4
S
0
1354
D
2229
D
Common Stock
2012-05-30
4
C
0
12500
A
14729
D
Common Stock
2012-05-30
4
S
0
12500
D
2229
D
Restricted Stock Units
2012-05-29
4
C
0
1354
A
Common Stock
1354
1354
D
Restricted Stock Unit
2012-05-30
4
C
0
12500
A
Common Stock
12500
12500
D
The shares were acquired by the reporting person as a result of the partial vesting of a restricted stock unit grant described below.
Not applicable.
The restricted stock units were scheduled to lapse on February 24, 2012. However, due to Company's black out policies and certain tax laws, the shares were not delivered to the reporting person until May 29, 2012.
The shares sold on this date were sold in multiple transactions. The actual sales prices range from $14.111-$14.1201. Upon request by the Securities and Exchange Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each price.
The restricted stock units were scheduled to lapse on January 7, 2012. However, due to Company's black out policies and certain tax laws, the shares were not delivered to the reporting person unitl May 30, 2012.
The shares sold on this date were sold in multiple transactions. The actual sales prices range from $13.57-$13.79. Upon request by the Securities and Exchange Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each price.
Each restricted stock unit represents a contingent right to receive one share of common stock.
Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal, annual installments commencing February 24, 2011. The second installment of 1,354 restricted stock units was scheduled to vest on February 24, 2012 but delivery of the shares was deferred as described herein.
Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in three installments. The first installment of 12,500 restricted stock units was scheduled to vest on January 7, 2012 but delivery of the shares was deferred as described herein. The remaining two installments of 6,250 restricted stock units each will vest on January 7, 2013 and January 7, 2014, respectively.
Nancy R. Smith, attorney-in-fact
2012-05-31
EX-24
2
powerofattorney.txt
POWER OF ATTORNEY
POWER OF ATTORNEY
For Executing Forms 3, 4 and 5
Know all by these present,that the undersigned hereby
constitutes and appoints each of Frank Thomas and
Nancy Smith, signing singly, his true and lawful
attorney-in-fact to:
(1) execute for and on behalf of the undersigned,in the
undersigneds capacity as an officer and/or director of
AMAG Pharmaceuticals, Inc., or the Company, Forms 3, 4 and 5
(including any amendments thereto) in accordance with Section
16(a) of the Securities Exchange Act of 1934,
as amended and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete
the execution of any such Forms 3, 4 and 5 and the timely filing
of such forms with the United States Securities and Exchange
Commission and any other authority; and
(3) take any other action of any type whatsoever in connection
with the foregoing which,in the opinion of such attorney-in-fact
may be of benefit to,in the best interest of,or legally required
by,the undersigned,it being understood that the documents
executed by such attorney-in-fact on behalf of the undersigned
pursuant to this Power of Attorney shall be in such form and
shall contain such terms and conditions as such attorney-in-fact
may approve in his discretion.
The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform all and every act and thing
whatsoever requisite, necessary and proper to be done in the
exercise of any of the rights and powers herein granted,as fully
to all intents and purposes as the undersigned might or could do
if personally present,with full power of substitution or revocation
hereby ratifying and confirming all that such attorney-in-fact, or
his substitute or substitutes, shall lawfully do or cause to be done
by virtue of this Power of Attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing
attorneys-in-fact, in serving in such capacity at the request of
the undersigned, are not assuming, nor is the Company assuming,
any of the undersigneds responsibilities to comply with Section 16
of the Securities Exchange Act of 1934, as amended.
This Power of Attorney replaces in their entirety any and all
prior powers of attorney executed by the undersigned with respect
to the subject matters set forth herein, including any powers of
attorney previously filed with the Securities and Exchange
Commission. This Power of Attorney shall remain in full force
and effect until the undersigned is no longer required to file
Forms 3, 4 and 5 with respect to the undersigneds holdings of and
transactions in securities issued by the Company, unless earlier
revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed this 23rd day of May 2012.
Signed: /s/ Lee F. Allen
Please Print: Lee F. Allen